|
1
|
Jemal A, Thomas A, Murray T and Thun M:
Cancer statistics, 2002. CA Cancer J Clin. 52:23–47. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Colombo PE, Fabbro M, Theillet C, Bibeau
F, Rouanet P and Ray-Coquard I: Sensitivity and resistance to
treatment in the primary management of epithelial ovarian cancer.
Crit Rev Oncol Hematol. 89:207–216. 2014. View Article : Google Scholar
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Seltzer V; NIH Consensus Development Panel
on Ovarian Cancer: NIH consensus conference. Ovarian cancer.
Screening, treatment, and follow-up. JAMA. 273:491–497. 1995.
View Article : Google Scholar
|
|
5
|
Kang KW, Lee MJ, Song JA, Jeong JY, Kim
YK, Lee C, Kim TH, Kwak Kb, Kim OJ and An HJ: Overexpression of
goosecoid homeobox is associated with chemoresistance and poor
prognosis in ovarian carcinoma. Oncol Rep. 32:189–198.
2014.PubMed/NCBI
|
|
6
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Turner N and Grose R: Fibroblast growth
factor signalling: From development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eswarakumar VP, Lax I and Schlessinger J:
Cellular signaling by fibroblast growth factor receptors. Cytokine
Growth Factor Rev. 16:139–149. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wiedemann M and Trueb B: Characterization
of a novel protein (FGFRL1) from human cartilage related to FGF
receptors. Genomics. 69:275–279. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zaid TM, Yeung TL, Thompson MS, Leung CS,
Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C,
Lopez-Berestein G, et al: Identification of FGFR4 as a potential
therapeutic target for advanced-stage, high-grade serous ovarian
cancer. Clin Cancer Res. 19:809–820. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang D, Zhu W, Li J, An C and Wang Z:
Serum concentrations of fibroblast growth factors 19 and 21 in
women with gestational diabetes mellitus: Association with insulin
resistance, adiponectin, and polycystic ovary syndrome history.
PLoS One. 8:e811902013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feng S, Dakhova O, Creighton CJ and
Ittmann M: Endocrine fibroblast growth factor FGF19 promotes
prostate cancer progression. Cancer Res. 73:2551–2562. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song KH, Li T, Owsley E, Strom S and
Chiang JY: Bile acids activate fibroblast growth factor 19
signaling in human hepatocytes to inhibit cholesterol
7alpha-hydroxylase gene expression. Hepatology. 49:297–305. 2009.
View Article : Google Scholar :
|
|
14
|
Stejskal D, Karpísek M, Hanulová Z and
Stejskal P: Fibroblast growth factor-19: Development, analytical
characterization and clinical evaluation of a new ELISA test. Scand
J Clin Lab Invest. 68:501–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie MH, Holcomb I, Deuel B, Dowd P, Huang
A, Vagts A, Foster J, Liang J, Brush J, Gu Q, et al: FGF-19, a
novel fibroblast growth factor with unique specificity for FGFR4.
Cytokine. 11:729–735. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang X, Ibrahimi OA, Olsen SK, Umemori H,
Mohammadi M and Ornitz DM: Receptor specificity of the fibroblast
growth factor family. The complete mammalian FGF family. J Biol
Chem. 281:15694–15700. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kurosu H, Choi M, Ogawa Y, Dickson AS,
Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA and
Kuro-o M: Tissue-specific expression of betaKlotho and fibroblast
growth factor (FGF) receptor isoforms determines metabolic activity
of FGF19 and FGF21. J Biol Chem. 282:26687–26695. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miura S, Mitsuhashi N, Shimizu H, Kimura
F, Yoshidome H, Otsuka M, Kato A, Shida T, Okamura D and Miyazaki
M: Fibroblast growth factor 19 expression correlates with tumor
progression and poorer prognosis of hepatocellular carcinoma. BMC
Cancer. 12:562012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ye YW, Zhou Y, Yuan L, Wang CM, Du CY,
Zhou XY, Zheng BQ, Cao X, Sun MH, Fu H, et al: Fibroblast growth
factor receptor 4 regulates proliferation and antiapoptosis during
gastric cancer progression. Cancer. 117:5304–5313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu YF, Yang XQ, Lu XF, Guo S, Liu Y, Iqbal
M, Ning SL, Yang H, Suo N and Chen YX: Fibroblast growth factor
receptor 4 promotes progression and correlates to poor prognosis in
cholangiocarcinoma. Biochem Biophys Res Commun. 446:54–60. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dutra RL, de Carvalho MB, Dos Santos M,
Mercante AM, Gazito D, de Cicco R, Group G, Tajara EH, Louro ID and
da Silva AM: FGFR4 profile as a prognostic marker in squamous cell
carcinoma of the mouth and oropharynx. PLoS One. 7:e507472012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li CS, Zhang SX, Liu HJ, Shi YL, Li LP,
Guo XB and Zhang ZH: Fibroblast growth factor receptor 4 as a
potential prognostic and therapeutic marker in colorectal cancer.
Biomarkers. 19:81–85. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sawey ET, Chanrion M, Cai C, Wu G, Zhang
J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, et al:
Identification of a therapeutic strategy targeting amplified FGF19
in liver cancer by oncogenomic screening. Cancer Cell. 19:347–358.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jaakkola S, Salmikangas P, Nylund S,
Partanen J, Armstrong E, Pyrhönen S, Lehtovirta P and Nevanlinna H:
Amplification of fgfr4 gene in human breast and gynecological
cancers. Int J Cancer. 54:378–382. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jones SA: Physiology of FGF15/19. Adv Exp
Med Biol. 728:171–182. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Potthoff MJ, Kliewer SA and Mangelsdorf
DJ: Endocrine fibroblast growth factors 15/19 and 21: From feast to
famine. Genes Dev. 26:312–324. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Doll KM, Kalinowski AK, Snavely AC, Irwin
DE, Bensen JT, Bae-Jump VL, Kim KH, Van Le L, Clarke-Pearson DL and
Gehrig PA: Obesity is associated with worse quality of life in
women with gynecologic malignancies: An opportunity to improve
patient-centered outcomes. Cancer. 121:395–402. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shah MM, Erickson BK, Matin T, McGwin G
Jr, Martin JY, Daily LB, Pasko D, Haygood CW, Fauci JM and Leath CA
III: Diabetes mellitus and ovarian cancer: More complex than just
increasing risk. Gynecol Oncol. 135:273–277. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thomson CA, E Crane T, Wertheim BC,
Neuhouser ML, Li W, Snetselaar LG, Basen-Engquist KM, Zhou Y and
Irwin ML: Diet quality and survival after ovarian cancer: Results
from the Women's Health Initiative. J Natl Cancer Inst.
106:1062014. View Article : Google Scholar
|
|
30
|
Olsen CM, Nagle CM, Whiteman DC, Ness R,
Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH, Risch HA, et al
Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer
Study Group: Ovarian Cancer Association Consortium: Obesity and
risk of ovarian cancer subtypes: Evidence from the Ovarian Cancer
Association Consortium. Endocr Relat Cancer. 20:251–262. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bae HS, Kim HJ, Hong JH, Lee JK, Lee NW
and Song JY: Obesity and epithelial ovarian cancer survival: A
systematic review and meta-analysis. J Ovarian Res. 7:412014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Katoh M and Nakagama H: FGF receptors:
Cancer biology and therapeutics. Med Res Rev. 34:280–300. 2014.
View Article : Google Scholar
|
|
33
|
Kotsopoulos J, Moody JR, Fan I, Rosen B,
Risch HA, McLaughlin JR, Sun P and Narod SA: Height, weight, BMI
and ovarian cancer survival. Gynecol Oncol. 127:83–87. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding W, Shi W, Bellusci S, Groffen J,
Heisterkamp N, Minoo P and Warburton D: Sprouty2 downregulation
plays a pivotal role in mediating crosstalk between TGF-beta1
signaling and EGF as well as FGF receptor tyrosine kinase-ERK
pathways in mesenchymal cells. J Cell Physiol. 212:796–806. 2007.
View Article : Google Scholar : PubMed/NCBI
|
